{'fraction_non_alphanumeric': 0.03564356435643564, 'fraction_numerical': 0.027722772277227723, 'mean_word_length': 5.39873417721519, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Acute and chronic effects of 3,4-dimethoxyphenylacetamide on plasma glucose and cholesterol in rats.

One hour after a single intraperitoneal dose of 50–200 mg./kg. of 3,4-dimethoxyphenylacetamide to satiated and 24-hr, fasted rats, plasma glucose was markedly increased but plasma cholesterol was reliably decreased only by the highest dose in one of two studies with satiated animals. At 24 hr. after the 10th daily oral drug administration, plasma cholesterol of rats was unaffected by 3,4-dimethoxyphenylacetamide (100 mg./kg.) but markedly decreased by a standard hypocholesterolemic agent (20,25-diazacholesterol). An acute, toxic effect of 3,4-dimethoxyphenylacetamide was indicated by a marked decrease in spontaneous motor activity and in body weight gain. Contrary to a previous suggestion, 3,4-dimelhoxyphenylacetamide does not appear to be a promising hypocholesterolemic agent; observations of acute hyperglycemia are at least partly attributable to the stressful effects of the toxic doses given.